https://www.selleckchem.com/products/sn-38.html
Histopathology findings in the gastrointestinal tract and lungs were noted but were not associated with a clear dose response and were likely incidental. Moreover, Lipocet® was just as well tolerated as the reference control. Therefore, 4,500 mg/kg body weight/day (the highest dose tested) was considered the no-observed-adverse-effect-level. These results support the safety of Lipocet® for use as a food ingredient.Opportunistic screening for osteoporosis can be performed using low-dose computed tomography (LDCT) imaging obtained for other
Like
Comment
Share
